Today's important announcements for Hong Kong stocks are as follows:
1) Company news
$SENSETIME-W (00020.HK)$ : After completing the strategic organizational restructuring, the company established a new “1+X” structure to better meet the opportunities and challenges brought about by the AI 2.0 era.
$YUEXIU PROPERTY (00123.HK)$: The cumulative contract sales for the first 11 months were 101.02 billion yuan, a year-on-year decrease of about 24%, accounting for 68.7% of the annual sales target.
$AGILE GROUP (03383.HK)$: The cumulative contract sales for the first 11 months were 14.75 billion yuan, a year-on-year decrease of 64.81%.
$ZIJIN MINING (02899.HK)$: Peru's La Arena gold mine and phase II project completed. As of June 30, 2024, the La Arena gold mine has a total confirmed + credible grade ore reserves of 22.6 million tons, containing about 8 tons of gold, with an average grade of 0.33 g/ton.
$MMG (01208.HK)$: Announced the main changes in mineral resources and ore reserves statements as of June 30, 2024: copper increased 17%, zinc increased 14%, lead increased 10%, molybdenum increased 62%, cobalt increased 10%, silver increased 11%, gold increased 5%, and no metals decreased.
$FANGZHOU JIANKE (06086.HK)$: Included as a constituent stock in the Hang Seng Hong Kong Listed Biotech Index.
$YUEXIU PROPERTY (00123.HK)$: An additional 1.9 billion yuan successfully competed for the Dongxiao Road plot in Haizhu District, Guangzhou.
$GAC GROUP (02238.HK)$: It is proposed to transfer 18.82% of Juwan Technology Research's shares for 1.331 billion yuan.
$GREENTOWN CHINA (03900.HK)$: It is proposed to sell all shares managed by Hangzhou Chenglin Lulong Enterprise for 0.4823 billion yuan.
$RYKADAN CAPITAL (02288.HK)$: Proposed sale of the property for a total of HK$0.1635 billion.
$ASIA ALLIED INF (00711.HK)$: It is proposed to acquire 51% of Wanbang Supply Chain (Hong Kong) shares for HK$47.5039 million.
$SHANDONG XINHUA (00719.HK)$: Azithromycin dry suspensions passed the consistent evaluation of generic drug quality and efficacy.
$LUYE PHARMA (02186.HK)$: Zanbijia has been approved for listing in mainland China. Up to now, Zanbijia has been approved for listing in 17 countries or regions around the world.
$HUTCHMED (00013.HK)$,$INNOVENT BIO (01801.HK)$: Jointly announced that Elute and Daboshu have been conditionally approved by China's State Drug Administration for the treatment of advanced endometrial cancer.
$ACOTEC-B (06669.HK)$: The registration application for paclitaxel release coronary balloon dilatation catheter ACOART CAMELLIA was approved by the China National Drug Administration.
$TG SMART ENERGY (01083.HK)$: Sale of shares in subsidiary companies to a special asset support program.
2) Repurchase news
$HUA HONG SEMI (01347.HK)$: We received a notice from shareholder Xinxin Hong Kong. From September 30 to December 2, 2024, the company's H shares were reduced by 17.726 million shares through a collective auction, and the shareholding ratio was reduced from 9.33% to 8.29%.
$TENCENT (00700.HK)$: Approximately HK$0.703 billion was spent to repurchase 1.76 million shares at a repurchase price of HK$395-404.2.
$AIA (01299.HK)$: Spend HK$61.6065 million to repurchase 1.0642 million shares at a repurchase price of HK$57.35-58.2.
$KUAISHOU-W (01024.HK)$: On December 3, it spent approximately HK$19.9505 million to repurchase 0.41 million shares.
$SINOPEC CORP (00386.HK)$: Spend HK$10.4458 million to repurchase 2.5 million shares at a repurchase price of HK$4.13-4.22.
Editor/Danial